PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, UK. lili.cui@astrazeneca.com.\', \'Department of Molecular & Integrative Physiology, University of Michigan Medical School Ann Arbor, Michigan 48109-5624, USA.\', \'Bioscience Renal, Research and Early Development, Cardiovascular, Renal & Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, UK.\', \'Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston 02451, USA.\', \'Global Lab Automation, Antibody Discovery & Protein Engineering, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1039/d1nr06858j
?:hasPublicationType
?:journal
  • Nanoscale
is ?:pmid of
?:pmid
?:pmid
  • 35024714
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.934
?:rankingScore_hIndex
  • 152
?:title
  • Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35024714>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35024714>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all